Small molecule · Inhibitor of nitric oxide synthase · developed by Heron Therapeutics
Tilarginine is a pan-nitric oxide synthase (NOS) inhibitor that binds and inhibits NOS, a free radical signaling molecule that promotes angiogenesis, metastasis and immunosuppression in the tumor microenvironment. Reducing NOS activity is intended to relieve tumor immunosuppression and enhance tumor antigen-specific immune responses.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06109428 | Phase 4 | Postoperative Pain | Completed | HRTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Analgesia
See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRTX catalysts and pipeline →